Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus

Thrombosis and Haemostasis

Volumn 116, Issue 6, 2016, Pages 1089-1099

  Santilli, Francesca ^a   Liani, Rossella ^a   Di Fulvio, Patrizia ^a   Formoso, Gloria ^a   Simeone, Paola ^a   Tripaldi, Romina ^a   Ueland, Thor ^b   Aukrust, Pål ^b   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adipokine; Diabetes mellitus; Insulin resistance; Oxidative stress; Platelet activation

Indexed keywords

ACARBOSE; CD40 LIGAND; DICKKOPF 1 PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSANOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; N(G),N(G) DIMETHYLARGININE; PLACEBO; RESISTIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET ACTIVATION; RESISTIN;

EID: 85004010399     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-06-0471     Document Type: Article

References (41)

1. Santilli F, Formoso G, Sbraccia P, et al. Postprandial hyperglycaemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010; 8: 828-837.
2. Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
3. Santilli F, Davì G, Consoli A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 391-397.
4. Lattanzio S, Santilli F, Liani R, et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. J Am Heart Assoc 2014; 3: pii: e001000.
5. Santilli F, Simeone P, Liani R, Davì G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat 2015; 120: 28-39.
6. Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
7. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-1196.
8. Trovati M, Mularoni EM, Burzacca S, et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-1322.
9. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
10. Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. Potential Biomarkers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease. J Endocrinol 2013; 2013: 698567.
11. Chen BH, Song Y, Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009; 32: 329-334.
12. Abate N, Sallam HS, Rizzo M, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 2014; 20: 4961-4969.
13. Fontana A, Spadaro S, Copetti M, et al. Association between Resistin Levels and All-Cause and Cardiovascular Mortality. A New Study and a Systematic Review and Meta-Analysis. Plos One 2015; 10: e0120419.
14. Ortega Moreno L, Lamacchia O, Fontana A, et al. The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity. Atherosclerosis 2016; 250: 23-29.
15. Derosa G, D’Angelo A, Salvadeo SA, et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009; 63: 723-733.
16. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39: S13-S22.
17. Chiasson JL, Josse RG, Gomis R, et al.; STOPNIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.
18. Khuu HM, Robinson CA, Goolsby K, et al. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med 1999; 123: 763-7.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Davì G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798.
21. Wang Z, Ciabattoni G, Créminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
22. Ciabattoni G, Maclouf J, Catella F, et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297.
23. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622-632.
24. Ottobelli Chielle E, de Souza WM, da Silva TP, et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin Biochem 2016; pii: S0009-912000005-9.
25. Tokuyama Y, Osawa H, Ishizuka T, et al. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism 2007; 56: 693-698.
26. Gharibeh MY, Al Tawallbeh GM, Abboud MM, et al. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010; 36: 443-449.
27. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007; 67: 215-225.
28. Nieva-Vazquez A, Pérez-Fuentes R, Torres-Rasgado E, et al. Serum resistin levels are associated with adiposity and insulin sensitivity in obese Hispanic subjects. Metab Syndr Relat Disord 2014; 12: 143-148.
29. Maggio AB, Wacker J, Montecucco F, et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 2012; 161: 1022-1027.
30. De Luis DA, Gonzalez Sagrado M, Conde R, et al. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. Clin Biochem 2011; 44: 1280-1283.
31. Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014; 37: 2813-2821.
32. Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679.
33. Cabrera de León A, Almeida González D, González Hernández A, et al. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb 2014; 21: 454-462.
34. Benomar Y, Amine H, Crépin D, et al. Central Resistin/TLR4 Impairs Adiponectin Signalling, Contributing to Insulin and FGF21 Resistance. Diabetes 2016; 65: 913-926.
35. Kang YE, Kim JM, Joung KH, et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLoS One 2016; 11e0154003.
36. Santilli F, Vazzana N, Liani R, et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
37. Gerrits AJ, Gitz E, Koekman CA, et al. Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica 2012; 97: 1149-1157.
38. Filkova M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009; 133: 157-170.
39. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an _uraemic toxin_ to a global cardiovascular risk molecule. Eur Clin Invest 2005; 35: 71-79.
40. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
41. Hu WL, Qian SB, Li JJ. Decreased C-reactive protein induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40: 201-206.